Updated on 2025/05/16

Information

 

写真a

 
TABATA KAORI
 
Organization
Faculty of Pharmaceutical Sciences Department of Chemo-Pharmaceutical Sciences Assistant Professor
School of Pharmaceutical Sciences Department of General Pharmaceutical Sciences(Concurrent)
Graduate School of Pharmaceutical Sciences Department of Medicinal Sciences(Concurrent)
Title
Assistant Professor
Contact information
メールアドレス
Profile
薬用植物に含まれる各種酵素や植物ホルモン応答因子の立体構造解析から反応メカニズムや基質の認識メカニズムを明らかにすることを目的として研究を行っている。 さらに、エクソソームに着目し、細胞間コミュニケーションや遺伝子あるいはタンパク質の発現制御のメカニズムについて研究を行っている。
External link

Research Areas

  • Life Science / Molecular biology

Degree

  • Ph.D.

Research History

  • Kyushu University  Assistant Professor 

Education

  • Kyushu University   大学院薬学府  

Research Interests・Research Keywords

  • Research theme: Development of the prevention and the therapeutic drug for COVID-19

    Keyword: COVID-19

    Research period: 2021.6 - 2025.6

  • Research theme: The role of exosome in the cell-cell communication

    Keyword: exosome

    Research period: 2019.4 - 2024.6

  • Research theme: Posttranslational regulation of CRF2 and impact on plant growth and development

    Keyword: cytokinin response factor

    Research period: 2017.4 - 2022.3

  • Research theme: Structural Basis for synthesis of tropane by polyketide synthase from Datura

    Keyword: polyketide synthase

    Research period: 2014.4

  • Research theme: Studies on the mechanism of cell death induced by cannabinoids

    Keyword: cell death

    Research period: 2013.1

  • Research theme: Structure and function analysis of heparanase involved in cancer metastasis

    Keyword: structural analysis

    Research period: 2010.6

  • Research theme: Silkworm expression of immune cell surface receptor

    Keyword: protein science

    Research period: 2007.4

  • Research theme: Structure and function of DNA replication related protein in Escherichia coli

    Keyword: structural analysis

    Research period: 2003.4

  • Research theme: Studies on the metabolic enzyme from medicinal plants

    Keyword: enzyme, cloning

    Research period: 2000.4

Papers

  • Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Reviewed International journal

    Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, Kimura KT, Deguchi S, Wang L, Lytras S, Tamura T, Kida I, Nasser H, Shofa M, Begum MM, Tsuda M, Oda Y, Suzuki T, Sasaki J, Sasaki-Tabata K, Fujita S, Yoshimatsu K, Ito H, Nao N, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Kuramochi J, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A, Matsuno K, Takayama K, Hashiguchi T, Tanaka S, Fukuhara T, Ikeda T, Sato K.

    Nat Commun.   14 ( 1 )   2671   2023.5

     More details

    Language:English  

    DOI: 10.1038/s41467-023-38188-

    researchmap

    Repository Public URL: https://hdl.handle.net/2324/7178718

  • Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Reviewed International journal

    Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, Nasser H, Shofa M, Oda Y, Lytras S, Nao N, Itakura Y, Deguchi S, Suzuki R, Wang L, Begum MM, Kita S, Yajima H, Sasaki J, @Sasaki-Tabata K, Shimizu R, Tsuda M, Kosugi Y, Fujita S, Pan L, Sauter D, Yoshimatsu K, Suzuki S, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Schreiber G, Maenaka K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Fukuhara T, Saito A, Tanaka S, Matsuno K, Takayama K, Sato K.

    Nat Commun.   16 ( 14(1) )   2800   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Repository Public URL: https://hdl.handle.net/2324/7183016

  • Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants including BA.4 and BA.5 Reviewed International journal

    Izumi Kimura, Daichi Yamasoba, Tomokazu Tamura, Naganori Nao, Tateki Suzuki, Yoshitaka Oda, Shuya Mitoma, Jumpei Ito, Hesham Nasser, Jiri Zahradnik, Keiya Uriu, Shigeru Fujita, Yusuke Kosugi, Lei Wang, Masumi Tsuda, Mai Kishimoto, Hayato Ito, Rigel Suzuki, Ryo Shimizu, M.S.T. Monira Begum, Kumiko Yoshimatsu, Kanako Terakado Kimura, Jiei Sasaki, Kaori Sasaki-Tabata, Yuki Yamamoto, Tetsuharu Nagamoto, Jun Kanamune, Kouji Kobiyama, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, Kotaro Shirakawa, Akifumi Takaori-Kondo, Jin Kuramochi, Gideon Schreiber, Ken J. Ishii, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Takao Hashiguchi, Terumasa Ikeda, Akatsuki Saito, Takasuke Fukuhara, Shinya Tanaka, Keita Matsuno, Kei Sato

    Cell   185 ( 21 )   3992 - 4007   2022.10   ISSN:00928674

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cell  

    After the global spread of the SARS-CoV-2 Omicron BA.2, some BA.2 subvariants, including BA.2.9.1, BA.2.11, BA.2.12.1, BA.4, and BA.5, emerged in multiple countries. Our statistical analysis showed that the effective reproduction numbers of these BA.2 subvariants are greater than that of the original BA.2. Neutralization experiments revealed that the immunity induced by BA.1/2 infections is less effective against BA.4/5. Cell culture experiments showed that BA.2.12.1 and BA.4/5 replicate more efficiently in human alveolar epithelial cells than BA.2, and particularly, BA.4/5 is more fusogenic than BA.2. We further provided the structure of the BA.4/5 spike receptor-binding domain that binds to human ACE2 and considered how the substitutions in the BA.4/5 spike play roles in ACE2 binding and immune evasion. Moreover, experiments using hamsters suggested that BA.4/5 is more pathogenic than BA.2. Our multiscale investigations suggest that the risk of BA.2 subvariants, particularly BA.4/5, to global health is greater than that of original BA.2.

    DOI: 10.1016/j.cell.2022.09.018

    Scopus

    PubMed

    researchmap

  • Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant Reviewed International journal

    Saito, Akatsuki; Tamura, Tomokazu; Zahradnik, Jiri; Deguchi, Sayaka; Tabata, Koshiro; Anraku, Yuki; Kimura, Izumi; Ito, Jumpei; Yamasoba, Daichi; Nasser, Hesham; Toyoda, Mako; Nagata, Kayoko; Uriu, Keiya; Kosugi, Yusuke; Fujita, Shigeru; Shofa, Maya; Begum, Mst Monira; Shimizu, Ryo; Oda, Yoshitaka; Suzuki, Rigel; Ito, Hayato; Nao, Naganori; Wang, Lei; Tsuda, Masumi; Yoshimatsu, Kumiko; Kuramochi, Jin; Kita, Shunsuke; @Sasaki-Tabata, Kaori; Fukuhara, Hideo; Maenaka, Katsumi; Yamamoto, Yuki; Nagamoto, Tetsuharu; Asakura, Hiroyuki; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Ueno, Takamasa; Schreiber, Gideon; Takaori-Kondo, Akifumi; Shirakawa, Kotaro; Sawa, Hirofumi; Irie, Takashi; Hashiguchi, Takao; Takayama, Kazuo; Matsuno, Keita; Tanaka, Shinya; Ikeda, Terumasa; Fukuhara, Takasuke; Sato, Kei

    CELL HOST & MICROBE   30 ( 9 )   1540 - 1555   2022.9   ISSN:19313128 eISSN:19346069

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

    DOI: 10.1016/j.chom.2022.10.003

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • Gibberellin DELLA signaling targets the retromer complex to redirect protein trafficking to the plasma membrane. Reviewed International journal

    Salanenka Y, Verstraeten I, Löfke C, Tabata K, Naramoto S, Glanc M and Friml J.

    Proc Natl Acad Sci U S A.   115 ( 14 )   3716 - 3721   2018.4

     More details

    Language:Japanese  

  • Silkworm expression and sugar profiling of human immune cell surface receptor, KIR2DL1 Reviewed International journal

    Sasaki K, Kajikawa M, Kuroki K, Motohashi T, Shimojima T, Park EY, Kondo S, Yagi H, Kato K, Maenaka K

    Biochem. Biophys. Res. Commun.   387 ( 3 )   2009.9

     More details

    Language:English  

  • Structural basis of the 3'-end recognition of a leading strand in stalled replication forks by PriA Reviewed International journal

    Sasaki K, Ose T, Okamoto N, Maenaka K, Tanaka T, Masai H, Saito M, Shirai T, Kohda D

    EMBO J.   26 ( 10 )   2007.5

     More details

    Language:English  

  • Crystallization and preliminary crystallographic analysis of the N-terminal domain of PriA from Escherichia coli Reviewed International journal

    Sasaki K, Ose T, Tanaka T, Mizukoshi T, Ishigaki T, Maenaka K, Masai H, Kohda D

    Biochim. Biophys. Acta   1764 ( 1 )   2006.1

     More details

    Language:English  

  • Molecular characterization of a novel beta-glucuronidase from Scutellaria baicalensis georgi Reviewed International journal

    Sasaki K, Taura F, Shoyama Y, Morimoto S

    J. Biol. Chem.   275 ( 35 )   27466 - 27472   2000.9

     More details

    Language:English  

  • Neutralizing immunity against coronaviruses in Tanzanian health care workers

    Barabona G., Ngare I., Kamori D., Nkinda L., Kosugi Y., Mawazo A., Ekwabi R., Kinasa G., Chuwa H., Sato K., Sunguya B., Ueno T., Matsuno K., Nao N., Sawa H., Tanaka S., Tsuda M., Wang L., Oda Y., Ferdous Z., Shishido K., Fukuhara T., Tamura T., Suzuki R., Suzuki S., Ito H., Kaku Y., Misawa N., Plianchaisuk A., Guo Z., Hinay A.A., Uriu K., Tolentino J.E.M., Chen L., Pan L., Suganami M., Chiba M., Yoshimura R., Yasuda K., Iida K., Ohsumi N., Strange A.P., Tanaka S., Yoshimura K., Sadamasu K., Nagashima M., Asakura H., Yoshida I., Nakagawa S., Shirakawa K., Takaori-Kondo A., Nagata K., Nomura R., Horisawa Y., Tashiro Y., Kawai Y., Takayama K., Hashimoto R., Deguchi S., Watanabe Y., Sakamoto A., Yasuhara N., Hashiguchi T., Suzuki T., Kimura K., Sasaki J., Nakajima Y., Yajima H., Irie T., Kawabata R., Tabata K., Ikeda T., Nasser H., Shimizu R., Begum M.S.T.M., Jonathan M., Mugita Y., Takahashi O., Ichihara K., Motozono C., Toyoda M., Saito A., Shofa M., Shibatani Y., Nishiuchi T.

    Scientific Reports   14 ( 1 )   2024.12

     More details

    Publisher:Scientific Reports  

    The ongoing vaccination efforts and exposure to endemic and emerging coronaviruses can shape the population's immunity against this group of viruses. In this study, we investigated neutralizing immunity against endemic and emerging coronaviruses in 200 Tanzanian frontline healthcare workers (HCWs). Despite low vaccination rates (19.5%), we found a high SARS-CoV-2 seroprevalence (94.0%), indicating high exposure in these HCWs. Next, we determined the neutralization capacity of antisera against human coronavirus NL63, and 229E, SARS-CoV-1, MERS-CoV and SARS-CoV-2 (including Omicron subvariants: BA.1, BQ.1.1 and XBB.1.5) using pseudovirus neutralization assay. We observed a broad range of neutralizing activity in HCWs, but no neutralization activity detected against MERS-CoV. We also observed a strong correlation between neutralizing antibody titers for SARS-CoV-2 and SARS-CoV-1, but not between other coronaviruses. Cross-neutralization titers against the newer Omicron subvariants, BQ.1.1 and XBB.1.5, was significantly reduced compared to BA.1 and BA.2 subvariants. On the other hand, the exposed vaccinated HCWs showed relatively higher median cross-neutralization titers against both the newer Omicron subvariants and SARS-CoV-1, but did not reach statistical significance. In summary, our findings suggest a broad range of neutralizing potency against coronaviruses in Tanzanian HCWs with detectable neutralizing immunity against SARS-CoV-1 resulting from SARS-CoV-2 exposure.

    DOI: 10.1038/s41598-024-55989-4

    Scopus

  • Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant

    Tsujino S., Deguchi S., Nomai T., Padilla-Blanco M., Plianchaisuk A., Wang L., Begum M.M., Uriu K., Mizuma K., Nao N., Kojima I., Tsubo T., Li J., Matsumura Y., Nagao M., Oda Y., Tsuda M., Anraku Y., Kita S., Yajima H., Sasaki-Tabata K., Guo Z., Hinay A.A., Yoshimatsu K., Yamamoto Y., Nagamoto T., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Nasser H., Jonathan M., Putri O., Kim Y., Chen L., Suzuki R., Tamura T., Maenaka K., Irie T., Matsuno K., Tanaka S., Ito J., Ikeda T., Takayama K., Zahradnik J., Hashiguchi T., Fukuhara T., Sato K.

    Microbiology and Immunology   68 ( 9 )   305 - 330   2024.9   ISSN:03855600

     More details

    Publisher:Microbiology and Immunology  

    In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo-electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.

    DOI: 10.1111/1348-0421.13165

    Scopus

  • Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236

    Fujita S., Plianchaisuk A., Deguchi S., Ito H., Nao N., Wang L., Nasser H., Tamura T., Kimura I., Kashima Y., Suzuki R., Suzuki S., Kida I., Tsuda M., Oda Y., Hashimoto R., Watanabe Y., Uriu K., Yamasoba D., Guo Z., Hinay A.A., Kosugi Y., Chen L., Pan L., Kaku Y., Chu H., Donati F., Temmam S., Eloit M., Yamamoto Y., Nagamoto T., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Suzuki Y., Sawa H., Mizuma K., Li J., Mimura Y., Ohari Y., Tsubo T., Ferdous Z., Shishido K., Mohri H., Iida M., Tsujino S., Misawa N., Usui K., Saikruang W., Lytras S., Kawakubo S., Nishumura L., Mendoza Tolentino J.E., Li W., Yo M.S., Horinaka K., Suganami M., Chiba M., Yoshimura R., Yasuda K., Iida K., Strange A.P., Ohsumi N., Tanaka S., Ogawa E., Okumura K., Fukuda T., Osujo R., Yoshida I., Nakagawa S., Takaori-Kondo A., Shirakawa K., Nagata K., Nomura R., Horisawa Y., Tashiro Y., Kawai Y., Nakata Y., Futatsusako H., Sakamoto A., Yasuhara N., Hashiguchi T., Suzuki T., Kimura K., Sasaki J., Nakajima Y., Yajima H., Irie T., Kawabata R., Sasaki-Tabata K., Shimizu R., Monira Begum M.S.T., Jonathan M., Mugita Y., Leong S., Takahashi O., Ichihara K., Ueno T., Motozono C.

    eBioMedicine   104   2024.6

     More details

    Publisher:eBioMedicine  

    Background: Although several SARS-CoV-2-related coronaviruses (SC2r-CoVs) were discovered in bats and pangolins, the differences in virological characteristics between SARS-CoV-2 and SC2r-CoVs remain poorly understood. Recently, BANAL-20-236 (B236) was isolated from a rectal swab of Malayan horseshoe bat and was found to lack a furin cleavage site (FCS) in the spike (S) protein. The comparison of its virological characteristics with FCS-deleted SARS-CoV-2 (SC2ΔFCS) has not been conducted yet. Methods: We prepared human induced pluripotent stem cell (iPSC)-derived airway and lung epithelial cells and colon organoids as human organ-relevant models. B236, SARS-CoV-2, and artificially generated SC2ΔFCS were used for viral experiments. To investigate the pathogenicity of B236 in vivo, we conducted intranasal infection experiments in hamsters. Findings: In human iPSC-derived airway epithelial cells, the growth of B236 was significantly lower than that of the SC2ΔFCS. A fusion assay showed that the B236 and SC2ΔFCS S proteins were less fusogenic than the SARS-CoV-2 S protein. The infection experiment in hamsters showed that B236 was less pathogenic than SARS-CoV-2 and even SC2ΔFCS. Interestingly, in human colon organoids, the growth of B236 was significantly greater than that of SARS-CoV-2. Interpretation: Compared to SARS-CoV-2, we demonstrated that B236 exhibited a tropism toward intestinal cells rather than respiratory cells. Our results are consistent with a previous report showing that B236 is enterotropic in macaques. Altogether, our report strengthens the assumption that SC2r-CoVs in horseshoe bats replicate primarily in the intestinal tissues rather than respiratory tissues. Funding: This study was supported in part by AMED ASPIRE (JP23jf0126002, to Keita Matsuno, Kazuo Takayama, and Kei Sato); AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers “UTOPIA” (JP223fa627001, to Kei Sato), AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP223fa727002, to Kei Sato); AMED SCARDA Hokkaido University Institute for Vaccine Research and Development (HU-IVReD) (JP223fa627005h0001, to Takasuke Fukuhara, and Keita Matsuno); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP21fk0108574, to Hesham Nasser; JP21fk0108493, to Takasuke Fukuhara; JP22fk0108617 to Takasuke Fukuhara; JP22fk0108146, to Kei Sato; JP21fk0108494 to G2P-Japan Consortium, Keita Matsuno, Shinya Tanaka, Terumasa Ikeda, Takasuke Fukuhara, and Kei Sato; JP21fk0108425, to Kazuo Takayama and Kei Sato; JP21fk0108432, to Kazuo Takayama, Takasuke Fukuhara and Kei Sato; JP22fk0108534, Terumasa Ikeda, and Kei Sato; JP22fk0108511, to Yuki Yamamoto, Terumasa Ikeda, Keita Matsuno, Shinya Tanaka, Kazuo Takayama, Takasuke Fukuhara, and Kei Sato; JP22fk0108506, to Kazuo Takayama and Kei Sato); AMED Research Program on HIV/AIDS (JP22fk0410055, to Terumasa Ikeda; and JP22fk0410039, to Kei Sato); AMED Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125008 to Keita Matsuno); AMED CREST (JP21gm1610005, to Kazuo Takayama; JP22gm1610008, to Takasuke Fukuhara; JST PRESTO (JPMJPR22R1, to Jumpei Ito); JST CREST (JPMJCR20H4, to Kei Sato); JSPS KAKENHI Fund for the Promotion of Joint International Research (International Leading Research) (JP23K20041, to G2P-Japan Consortium, Keita Matsuno, Takasuke Fukuhara and Kei Sato); JST SPRING (JPMJSP2108 to Shigeru Fujita); JSPS KAKENHI Grant-in-Aid for Scientific Research C (22K07103, to Terumasa Ikeda); JSPS KAKENHI Grant-in-Aid for Scientific Research B (21H02736, to Takasuke Fukuhara); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (22K16375, to Hesham Nasser; 20K15767, to Jumpei Ito); JSPS Core-to-Core Program (A. Advanced Research Networks) (JPJSCCA20190008, to Kei Sato); JSPS Research Fellow DC2 (22J11578, to Keiya Uriu); JSPS Research Fellow DC1 (23KJ0710, to Yusuke Kosugi); JSPS Leading Initiative for Excellent Young Researchers (LEADER) (to Terumasa Ikeda); World-leading Innovative and Smart Education (WISE) Program 1801 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (to Naganori Nao); Ministry of Health, Labour and Welfare (MHLW) under grant 23HA2010 (to Naganori Nao and Keita Matsuno); The Cooperative Research Program (Joint Usage/Research Center program) of Institute for Life and Medical Sciences, Kyoto University (to Kei Sato); International Joint Research Project of the Institute of Medical Science, the University of Tokyo (to Terumasa Ikeda and Takasuke Fukuhara); The Tokyo Biochemical Research Foundation (to Kei Sato); Takeda Science Foundation (to Terumasa Ikeda and Takasuke Fukuhara); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to Terumasa Ikeda); The Naito Foundation (to Terumasa Ikeda); Hokuto Foundation for Bioscience (to Tomokazu Tamura); Hirose Foundation (to Tomokazu Tamura); and Mitsubishi Foundation (to Kei Sato).

    DOI: 10.1016/j.ebiom.2024.105181

    Scopus

  • Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

    Tamura Tomokazu, Irie Takashi, Deguchi Sayaka, Yajima Hisano, Tsuda Masumi, Nasser Hesham, Mizuma Keita, Plianchaisuk Arnon, Suzuki Saori, Uriu Keiya, Begum Mst Monira, Shimizu Ryo, Jonathan Michael, Suzuki Rigel, Kondo Takashi, Ito Hayato, Kamiyama Akifumi, Yoshimatsu Kumiko, Shofa Maya, Hashimoto Rina, Anraku Yuki, Terakado Kimura Kanako, Kita Shunsuke, Sasaki Jiei, Sasaki-Tabata Kaori, Maenaka Katsumi, Nao Naganori, Wang Lei, Oda Yoshitaka, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Sawa Hirofumi, Kawabata Ryoko, Watanabe Yukio, Sakamoto Ayaka, Yasuhara Naoko, Suzuki Tateki, Nakajima Yukari, Ferdous Zannatul, Shishido Kenji, Mugita Yuka, Takahashi Otowa, Ichihara Kimiko, Kaku Yu, Misawa Naoko, Guo Ziyi, Hinay Alfredo, Kosugi Yusuke, Fujita Shigeru, Tolentino Jarel M., Chen Luo, Pan Lin, Suganami Mai, Chiba Mika, Yoshimura Ryo, Yasuda Kyoko, Iida Keiko, Ohsumi Naomi, Strange Adam P., Shibatani Yuki, Nishiuchi Tomoko, Tanaka Shiho, Putri Olivia, Joas Gustav, Kim Yoonjin, Yamasoba Daichi, Yoshimura Kazuhisa, Sadamasu Kenji, Nagashima Mami, Asakura Hiroyuki, Takaori-Kondo Akifumi, Nagata Kayoko, Kawai Yugo, Ueno Takamasa, Motozono Chihiro, Toyoda Mako, Ikeda Terumasa, Saito Akatsuki, Matsuno Keita, Ito Jumpei, Tanaka Shinya, Sato Kei, Hashiguchi Takao, Takayama Kazuo, Fukuhara Takasuke

    Nature Communications   15 ( 1 )   1176   2024.2   eISSN:20411723

     More details

    Language:English   Publisher:Springer  

    Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.

    DOI: 10.1038/s41467-024-45274-3

    Scopus

    CiNii Research

  • Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Reviewed International journal

    Tamura T, Irie T, Deguchi S, Yajima H, Tsuda M, Nasser H, Mizuma K, Plianchaisuk A, Suzuki S, Uriu K, Begum MM, Shimizu R, Jonathan M, Suzuki R, Kondo T, Ito H, Kamiyama A, Yoshimatsu K, Shofa M, Hashimoto R, Anraku Y, Kimura KT, Kita S, Sasaki J, @Sasaki-Tabata K, Maenaka K, Nao N, Wang L, Oda Y; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ikeda T, Saito A, Matsuno K, Ito J, Tanaka S, Sato K, Hashiguchi T, Takayama K, Fukuhara T.

    Nat Commun.   15 ( 1 )   1176   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Repository Public URL: https://hdl.handle.net/2324/7182182

  • Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5

    Tamura T., Yamasoba D., Oda Y., Ito J., Kamasaki T., Nao N., Hashimoto R., Fujioka Y., Suzuki R., Wang L., Ito H., Kashima Y., Kimura I., Kishimoto M., Tsuda M., Sawa H., Yoshimatsu K., Yamamoto Y., Nagamoto T., Kanamune J., Suzuki Y., Ohba Y., Suzuki S., Kato M., Ferdous Z., Mouri H., Shishido K., Misawa N., Uriu K., Kosugi Y., Fujita S., Suganami M., Chiba M., Yoshimura R., Nakagawa S., Wu J., Takaori-Kondo A., Shirakawa K., Nagata K., Kazuma Y., Nomura R., Horisawa Y., Tashiro Y., Kawai Y., Hashiguchi T., Suzuki T., Kimura K., Sasaki J., Nakajima Y., Sakamoto A., Yasuhara N., Irie T., Kawabata R., Ikeda T., Nasser H., Shimizu R., Begum M., Takahashi O., Ichihara K., Ueno T., Motozono C., Toyoda M., Saito A., Tanaka Y.L., Butlertanaka E.P., Shofa M., Tabata K., Yokota I., Matsuno K., Takayama K., Tanaka S., Sato K., Fukuhara T.

    Communications Biology   6 ( 1 )   2023.12

     More details

    Publisher:Communications Biology  

    The unremitting emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants necessitates ongoing control measures. Given its rapid spread, the new Omicron subvariant BA.5 requires urgent characterization. Here, we comprehensively analyzed BA.5 with the other Omicron variants BA.1, BA.2, and ancestral B.1.1. Although in vitro growth kinetics of BA.5 was comparable among the Omicron subvariants, BA.5 was much more fusogenic than BA.1 and BA.2. Airway-on-a-chip analysis showed that, among Omicron subvariants, BA.5 had enhanced ability to disrupt the respiratory epithelial and endothelial barriers. Furthermore, in our hamster model, in vivo pathogenicity of BA.5 was slightly higher than that of the other Omicron variants and less than that of ancestral B.1.1. Notably, BA.5 gains efficient virus spread compared with BA.1 and BA.2, leading to prompt immune responses. Our findings suggest that BA.5 has low pathogenicity compared with the ancestral strain but enhanced virus spread /inflammation compared with earlier Omicron subvariants.

    DOI: 10.1038/s42003-023-05081-w

    Scopus

  • Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines

    Yamane, D; Tetsukawa, R; Zenmyo, N; Tabata, K; Yoshida, Y; Matsunaga, N; Shindo, N; Ojida, A

    JOURNAL OF MEDICINAL CHEMISTRY   66 ( 13 )   9130 - 9146   2023.7   ISSN:0022-2623 eISSN:1520-4804

     More details

    Language:English   Publisher:Journal of Medicinal Chemistry  

    The choice of an appropriate electrophile is crucial in the design of targeted covalent inhibitors (TCIs). In this report, we systematically investigated the glutathione (GSH) reactivity of various haloacetamides and the aqueous stability of their thiol adducts. Our findings revealed that dihaloacetamides cover a broad range of GSH reactivity depending on the combination of the halogen atoms and the structure of the amine scaffold. Among the dihaloacetamides, dichloroacetamide (DCA) exhibited slightly lower GSH reactivity than chlorofluoroacetamide (CFA). The DCA-thiol adduct is readily hydrolyzed under aqueous conditions, but it can stably exist in the solvent-sequestered binding pocket of the protein. These reactivity profiles of DCA were successfully exploited in the design of TCIs targeting noncatalytic cysteines of KRASG12C and EGFRL858R/T790M. These inhibitors exhibited strong antiproliferative activities against cancer cells. Our findings provide valuable insights for designing dihaloacetamide-based reversible covalent inhibitors.

    DOI: 10.1021/acs.jmedchem.3c00737

    Web of Science

    Scopus

    PubMed

  • Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines Reviewed International journal

    #Yamane D, #Tetsukawa R, @Zenmyo N, @Tabata K, @Yoshida Y, @Matsunaga N, @Shindo N, @Ojida A.

    J Med Chem.   66 ( 13 )   9130 - 9146   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Repository Public URL: https://hdl.handle.net/2324/7174357

  • Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants International journal

    Tamura Tomokazu, Ito Jumpei, Uriu Keiya, Zahradnik Jiri, Kida Izumi, Anraku Yuki, Nasser Hesham, Shofa Maya, Oda Yoshitaka, Lytras Spyros, Nao Naganori, Itakura Yukari, Deguchi Sayaka, Suzuki Rigel, Wang Lei, Begum MST Monira, Kita Shunsuke, Yajima Hisano, Sasaki Jiei, Sasaki-Tabata Kaori, Shimizu Ryo, Tsuda Masumi, Kosugi Yusuke, Fujita Shigeru, Pan Lin, Sauter Daniel, Yoshimatsu Kumiko, Suzuki Saori, Asakura Hiroyuki, Nagashima Mami, Sadamasu Kenji, Yoshimura Kazuhisa, Yamamoto Yuki, Nagamoto Tetsuharu, Schreiber Gideon, Maenaka Katsumi, The Genotype to Phenotype Japan (G2P-Japan), Hashiguchi Takao, Ikeda Terumasa, Fukuhara Takasuke, Saito Akatsuki, Tanaka Shinya, Matsuno Keita, Takayama Kazuo, Sato Kei

    Nature Communications   14 ( 1 )   2800 - 2800   2023   eISSN:20411723

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Nature  

    In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.

    DOI: 10.1038/s41467-023-38435-3

    Scopus

    PubMed

    CiNii Research

    researchmap

  • Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay

    Nasser H., Shimizu R., Ito J., Matsuno K., Nao N., Sawa H., Kishimoto M., Tanaka S., Tsuda M., Wang L., Oda Y., Kato M., Ferdous Z., Mouri H., Shishido K., Fukuhara T., Tamura T., Suzuki R., Ito H., Yamasoba D., Kimura I., Misawa N., Uriu K., Kosugi Y., Fujita S., Suganami M., Chiba M., Yoshimura R., Nakagawa S., Wu J., Takaori-Kondo A., Shirakawa K., Nagata K., Kazuma Y., Nomura R., Horisawa Y., Tashiro Y., Kawai Y., Irie T., Kawabata R., Begum M.M., Takahashi O., Ichihara K., Ueno T., Motozono C., Toyoda M., Tanaka Y.L., Butlertanaka E.P., Shofa M., Takayama K., Hashimoto R., Deguchi S., Hashiguchi T., Suzuki T., Kimura K., Sasaki J., Nakajima Y., Tabata K., Saito A., Sato K., Ikeda T.

    STAR Protocols   3 ( 4 )   2022.12

     More details

    Publisher:STAR Protocols  

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein mediates membrane fusion between the virus and the target cells, triggering viral entry into the latter. Here, we describe a SARS-CoV-2 spike-protein-mediated membrane fusion assay using a dual functional split reporter protein to quantitatively monitor the fusion kinetics of the viral and target cell membranes in living cells. This approach can be applied in various cell types, potentially predicting the pathogenicity of newly emerging variants. For complete details on the use and execution of this protocol, please refer to Kimura et al. (2022b), Kimura et al. (2022c), Motozono et al. (2021), Saito et al. (2022a), Saito et al. (2022b), Suzuki et al. (2022), and Yamasoba et al. (2022).

    DOI: 10.1016/j.xpro.2022.101773

    Scopus

  • Glutamate release from astrocyte cell-line GL261 via alterations in the intracellular ion environment. Reviewed International journal

    Ono K, Suzuki H, Higa M, Tabata K, Sawada M

    J Neural Transm.   121 ( 3 )   245 - 257   2014.3

     More details

    Language:Japanese  

  • Preparation of a Monoclonal Antibody against Notoginsenoside R1, a Distinctive Saponin from Panax notoginseng, and Its Application to Indirect Competitive ELISA. Reviewed International journal

    Limsuwanchote S, Wungsintaweekul J, Yusakul G, Han JY, Sasaki-Tabata K, Tanaka H, Shoyama Y, Morimoto S

    Planta Med.   80 ( 4 )   337 - 342   2014.3

     More details

    Language:English  

  • Development of an Enzyme Immunoassay Using a Monoclonal Antibody against the Psychoactive Diterpenoid Salvinorin A. Reviewed International journal

    Paudel MK, Shirota O, Sasaki-Tabata K, Tanaka H, Sekita S, Morimoto S

    J. Nat. Prod.   27 ( 76(9) )   1654 - 1660   2013.9

     More details

    Language:English  

  • Development of an indirect competitive enzyme-linked immunosorbent assay (icELISA) using highly specific monoclonal antibody against paclitaxel. Reviewed International journal

    Chao Z, Tan M, Paudel MK, Sakamoto S, Ma L, Sasaki-Tabata K, Tanaka H, Shoyama Y, Xuan L, Morimoto S

    J. Nat. Med.   67 ( 3 )   512 - 518   2013.7

     More details

    Language:English  

  • Silkworm Baculovirus Expression System for Molecular Medicine Reviewed International journal

    Mizuho Kajikawa, Kaori Sasaki-Tabata, Hideo Fukuhara, Masataka Horiuchi, Yuki Okabe, Katsumi Maenaka

    Journal of Biotechnology & Biomaterials   2012.3

     More details

    Language:English  

  • Preparation of a single-chain variable fragment and a recombinant antigen-binding fragment against the anti-malarial drugs, artemisinin and artesunate, and their application in an ELISA. Reviewed International journal

    Paudel MK, Takei A, Sakoda J, Juengwatanatrakul T, Sasaki-Tabata K, Putalun W, Shoyama Y, Tanaka H, Morimoto S

    Anal Chem   84 ( 4 )   2002 - 2008   2012.2

     More details

    Language:English  

  • Flavone-catalyzed apoptosis in Scutellaria baicalensis. Reviewed International journal

    Hirunuma M, Shoyama Y, Sasaki K, Sakamoto S, Taura F, Shoyama Y, Tanaka H, Morimoto S.

    Phytochemistry.   72 ( 8 )   2011.6

     More details

    Language:English  

  • A fluorescent single domain antibody against plumbagin expressed in silkworm larvae for fluorescence-linked immunosorbent assay (FLISA). Reviewed International journal

    Sakamoto S, Pongkitwitoon B, Sasaki-Tabata K, Putalun W, Maenaka K, Tanaka H, Morimoto S.

    Analyst.   136 ( 10 )   2011.5

     More details

    Language:English  

  • Construction, Expression, and Characterization of a Single-Chain Variable Fragment Antibody Against 2,4-Dichlorophenoxyacetic Acid in the Hemolymph of Silkworm Larvae. Reviewed International journal

    Sakamoto S, Pongkitwitoon B, Nakamura S, Sasaki-Tabata K, Tanizaki Y, Maenaka K, Tanaka H, Morimoto S.

    Appl Biochem Biotechnol.   2011.1

     More details

    Language:English  

  • Molecular basis for E-cadherin recognition by killer cell lectin-like receptor G1 (KLRG1) Reviewed International journal

    Nakamura S, Kuroki K, Ohki I, Sasaki K, Kajikawa M, Maruyama T, Ito M, Kameda Y, Ikura M, Yamamoto K, Matsumoto N, Maenaka K

    J. Biol. Chem.   284 ( 40 )   2009.10

     More details

    Language:English  

  • Ferritin reporter used for gene expression imaging by magnetic resonance Reviewed International journal

    Ono K, Fuma K, Tabata K, Sawada M

    Biochem. Biophys. Res. Commun.   388   2009.10

     More details

    Language:English  

  • Efficient silkworm expression of human GPCR (nociceptin receptor) by a Bombyx mori Bacmid DNA system Reviewed International journal

    Kajikawa M, Sasaki K, Wakimoto Y, Toyooka M, Motohashi T, Shimojima T, Takeda S, Park EY, Maenaka K

    Biochem. Biophys. Res. Commun   385 ( 3 )   2009.7

     More details

    Language:English  

  • Homogeneous sugar modification improves crystallization of measles virus hemagglutinin Reviewed International journal

    Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, Sasaki K, Kohda D, Yanagi Y, Maenaka K

    J. Virol. Methods   149 ( 1 )   2008.4

     More details

    Language:English  

  • Crystal structure of measles virus hemagglutinin provides insight into effective vaccines Reviewed International journal

    Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, Sasaki K, Kohda D, Yanagi Y, Maenaka K

    Proc. Natl. Acad. Sci. U S A   104 ( 49 )   2007.12

     More details

    Language:English  

  • Escherichia coli PriA protein, two modes of DNA binding and activation of ATP hydrolysis Reviewed International journal

    Tanaka T, Mizukoshi T, Sasaki K, Kohda D, Masai H

    J. Biol. Chem.   282 ( 27 )   2007.7

     More details

    Language:English  

  • Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells Reviewed International journal

    Morimoto S, Tanaka Y, Sasaki K, Tanaka H, Fukamizu T, Shoyama Y, Shoyama Y, Taura F

    J. Biol. Chem.   282 ( 28 )   2007.7

     More details

    Language:English  

▼display all

Presentations

  • 血清由来エクソソームを介した血液脳関門細胞におけるMRP4の発現変動解析

    @田畑 香織、#水野 颯人、@廣田 豪、@家入 一郎

    第7回日本臨床薬理学会九州・沖縄地方会  2023.7 

     More details

    Event date: 2024.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:九州大学医学部 百年講堂   Country:Japan  

  • Cloning, expression and characterization of polyketide synthase gene from Scopolia Japonica International conference

    Sasaki-Tabata K, Matsuo A, Fuchida H, Ojida A, Tanaka H and Morimoto S

    The 9th CSP-KSP-JSP Joint Symposium on Pharmacognosy  2016.5 

     More details

    Event date: 2016.5

    Language:English  

    Venue:Shanghai University of Traditional Chinese Medicine   Country:China  

    BACKGROUND AND PURPOSE: Various important pharmacological compounds such as atropine and scopolamine are included in Scopolia japonica. These compounds are synthesized using ornithine as a starting material, however, it’s unclear which enzyme catalyzes the tropinone synthesis reaction. Hence, in the present study we aimed to identify function and structure of novel polyketide synthase (PKS) from S. japonica.
    EXPERIMENTAL APPROACH: A total RNA was extracted from leaves of S. japonica and cDNA was synthesized using a reverse transcriptase. Then, degenerate PCR, 5' and 3' RACE was performed using cDNA as a template. Two novel genes were obtained and expressed in E. coli. The recombinant protein was purified with affinity column and ion exchange column. We analyzed the enzyme activity using HPLC. Moreover, we crystallized and performed crystallographic analysis of PKS.
    KEY RESULTS: Two novel genes of PKS from S. japonica were obtained. The recombinant PKSs expressed in E. coli as a soluble fraction was highly purified using affinity and ion exchange column and the enzyme assay with HPLC showed that new compounds were synthesized using some substrates. Moreover, crystallization screening resulted in obtaining needle or plate crystals. We could get single crystals in an optimized condition. The crystal diffracted to 2.0 angstrom at KEK-PF and the structures of PKS were determined using molecular replacement method.
    CONCLUSION AND IMPLICATIONS: These PKS genes seem to belong to PKS family because they showed high similarity to other CHS from various plants. These novel findings may contribute to clarifying the mechanism of tropane synthesis.

  • ハシリドコロ由来新規ポリケタイド合成酵素に関する研究

    田畑香織, 松尾彩加, 渕田大和, 王子田 彰夫, 田中 宏幸, 森元 聡

    日本生薬学会 第62回年会  2015.9 

     More details

    Event date: 2015.9

    Language:Japanese  

    Venue:長良川国際会議場(岐阜)   Country:Japan  

  • BmNPVバクミドシステムを用いたカイコでの膜タンパク質の発現

    佐々木香織, 梶川瑞穂, 前仲勝実

    第11回日本蛋白質科学会年会  2011.6 

     More details

    Event date: 2011.6

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

    タンパク質の機能解析や構造解析を行うにあたって大量のタンパク質の調製が必要となるが、真核生物由来のタンパク質を生理活性を保持した状態で調製するには大腸菌を用いた発現系では困難な場合が多い。
    そこで、我々はバキュロウイルスを利用した昆虫細胞発現系の発展型として、カイコバキュロウイルス(BmNPV)バクミドDNAと、大量生産の期待できるカイコ個体を組み合わせた発現システムを構築した。バキュロウイルスを用いた外来遺伝子の発現系では糖鎖が付加されたものが得られるため、大変有用である。さらに、BmNPVバクミドシステムはカイコに感染可能なバクミドDNAを大腸菌で簡便に作製することができ、ウイルスのタイターを測定するような煩雑な操作が不要である点で優れている。
    このBmNPVバクミドシステムを用いて、大腸菌で発現が難しいとされるヒト免疫受容体やGPCRのような膜タンパク質を活性を保持した状態で調製に成功した例を紹介する。

  • BmNPVバクミドシステムによるヒト免疫細胞表面レセプターの発現と糖鎖解析

    佐々木香織, 梶川瑞穂, 矢木宏和, 近藤幸子, 黒木喜美子, 本橋智子, 霜島司, 朴龍洙, 加藤晃一, 前仲勝実

    第31回日本分子生物学会年会・第81回日本生化学会大会 合同大会  2008.12 

     More details

    Event date: 2008.12

    Language:Others  

    Venue:神戸   Country:Japan  

  • BmNPVバクミドシステムによるヒト免疫細胞表面レセプターの発現と糖鎖解析

    佐々木香織, 梶川瑞穂, 矢木宏和, 近藤幸子, 黒木喜美子, 本橋智子, 霜島司, 朴龍洙, 加藤晃一, 前仲勝実

    第8回日本蛋白質科学会年会  2008.6 

     More details

    Event date: 2008.6

    Language:Others  

    Venue:東京   Country:Japan  

  • Structural basis for the DNA recognition of PriA protein in the stalled DNA replication fork

    佐々木香織, 田中卓, 正井久雄, 前仲勝実, 神田大輔

    第30回日本分子生物学会年会・第80回日本生化学会大会 合同大会  2007.12 

     More details

    Event date: 2007.12

    Language:Others  

    Venue:横浜   Country:Japan  

  • PriAタンパク質によるDNA 3’末端の塩基非選択的認識機構の解明

    佐々木香織, 尾瀬農之, 岡本直明, 田中卓, 前仲勝実, 正井久雄, 斉藤美保子, 白井剛, 神田大輔

    第7回日本蛋白質科学会年会  2007.5 

     More details

    Event date: 2007.5

    Language:Others  

    Venue:仙台   Country:Japan  

  • Structural basis for the recognition of the 3'-terminus of DNA by PriA protein International conference

    Kaori Sasaki, Toyoyuki Ose, Taku Tanaka, Naoaki Okamoto, Katsumi Maenaka, Tsuyoshi Shirai, Hisao Masai and Daisuke Kohda

    20th IUBMB International Congress of Biochemistry and Molecular Biology and 11th FAOBMB Congress  2006.6 

     More details

    Event date: 2006.6

    Language:Others  

    Venue:京都   Country:Japan  

  • BmNPVバクミドシステムを用いたカイコ個体でのヒト免疫細胞表面レセプターKIRの大量発現

    佐々木香織, 梶川瑞穂, 黒木喜美子, 本橋智子, 霜島司, 朴龍洙, 神田大輔, 前仲勝実

    第6回日本蛋白質科学会年会  2006.4 

     More details

    Event date: 2006.4

    Language:Others  

    Venue:京都   Country:Japan  

  • E. coli 由来PriAのN末端ドメインによるDNA 3’末端認識の構造的基盤

    佐々木香織, 尾瀬農之, 田中卓, 岡本直明, 前仲勝実, 正井久雄, 神田大輔

    文部科学省タンパク3000プロジェクト 第4回産学連携フォーラムin福岡  2006.3 

     More details

    Event date: 2006.3

    Language:Others  

    Venue:福岡   Country:Japan  

  • E. coli 由来PriAのN末端ドメインによるDNA 3’末端認識の構造的基盤

    佐々木香織, 尾瀬農之, 田中卓, 岡本直明, 前仲勝実, 正井久雄, 神田大輔

    第28回日本分子生物学会年会  2005.12 

     More details

    Event date: 2005.12

    Language:Others  

    Venue:福岡   Country:Japan  

  • E. coli 由来PriAのN末端ドメインによるDNA 3’末端認識の構造的基盤

    佐々木香織, 尾瀬農之, 田中卓, 岡本直明, 前仲勝実, 正井久雄, 神田大輔

    日本バイオインフォマティクス学会 第1回プロテイン・インフォマティクスワークショップin九州  2005.10 

     More details

    Event date: 2005.10

    Language:Others  

    Venue:福岡   Country:Japan  

  • Structural analysis of the N-terminal domain of PriA from E. coli International conference

    Kaori Sasaki, Toyoyuki Ose, Taku Tanaka, Toshimi Mizukoshi, Tomoko Ishigaki, Naoaki Okamoto, Katsumi Maenaka, Hisao Masai and Daisuke Kohda

    XX Congress of he International Union of Crystallography  2005.8 

     More details

    Event date: 2005.8

    Language:Others  

    Venue:Florence   Country:Italy  

  • Structural basis for the stalled replication folk recognition by E. coli PriA International conference

    Kaori Sasaki

    第1回 研究所ネットワーク国際シンポジウム  2005.7 

     More details

    Event date: 2005.7

    Language:Others  

    Venue:東京   Country:Japan  

  • E. coli 由来PriAのN末端ドメインの立体構造解析

    佐々木香織, 尾瀬農之, 田中卓, 前仲勝実, 正井久雄, 神田大輔

    第5回日本蛋白質科学会年会  2005.6 

     More details

    Event date: 2005.6 - 2005.7

    Language:Others  

    Venue:福岡   Country:Japan  

  • 大腸菌由来PriAとオリゴヌクレオチドとの複合体の結晶化

    佐々木香織, 尾瀬農之, 岡本直明, 田中卓, 正井久雄, 前仲勝実, 神田大輔

    第27回日本分子生物学会年会  2004.12 

     More details

    Event date: 2004.12

    Language:Others  

    Venue:神戸   Country:Japan  

  • 大腸菌由来PriAとオリゴヌクレオチドとの複合体の結晶化

    佐々木香織, 岡本直明, 田中卓, 正井久雄, 前仲勝実, 神田大輔

    日本結晶学会 2003年度年会  2003.12 

     More details

    Event date: 2003.12

    Language:Others  

    Venue:熊本   Country:Japan  

  • コガネバナのフラボノイド代謝に関する研究

    佐々木香織, Prakairoong Pattanakachorn, 森元聡, 正山征洋

    日本薬学会 第121回年会  2001.3 

     More details

    Event date: 2001.3

    Language:Others  

    Venue:札幌   Country:Japan  

  • コガネバナのフラボノイド代謝酵素に関する研究

    佐々木香織, 田浦太志, 森元聡, 正山征洋

    日本生薬学会 第47回年会  2000.9 

     More details

    Event date: 2000.9

    Language:Others  

    Venue:所沢   Country:Japan  

  • コガネバナのbaicalin代謝酵素に関する研究

    佐々木香織, 田浦太志, 森元聡, 正山征洋

    日本生薬学会 第46回年会  1999.9 

     More details

    Event date: 1999.9

    Language:Others  

    Venue:大阪   Country:Japan  

  • Exosomeを介した血液脳関門における薬物トランスポーター発現制御機構の解明

    @廣田 豪、#水野 颯人、@田畑 香織、@家入 一郎

    第39回日本TDM学会・学術大会  2023.6 

     More details

    Event date: 2023.6

    Language:Japanese  

    Venue:京都テルサ   Country:Japan  

  • システイン化学修飾を利用したタンパク質化学切断法の開発:②Cysホルミル化によるタンパク質配列選択的切断および細胞表層応用

    善明 直輝, 松本 侑也, 安田 斉弘, 内之宮 祥平, 進藤 直哉, 田畑 香織, 王子田 彰夫

    日本薬学会 第143年会(札幌)  2023.3 

     More details

    Event date: 2023.3

    Language:Japanese  

    Venue:札幌   Country:Japan  

  • システイン化学修飾を利用したタンパク質化学切断法の開発:1. システインホルミル化の化学特性解明

    松本 侑也, 善明 直輝, 安田 斉弘, 内之宮 祥平, 進藤 直哉, 田畑 香織, 王子田 彰夫

    日本薬学会 第143年会(札幌)  2023.3 

     More details

    Event date: 2023.3

    Language:Japanese  

    Venue:札幌   Country:Japan  

  • システイン化学修飾を利用したタンパク質化学切断法の開発:1. システインホルミル化の化学特性解明

    松本 侑也, 善明 直輝, 安田 斉弘, 内之宮 祥平, 進藤 直哉, 田畑 香織, 王子田 彰夫

    日本薬学会 第143年会(札幌)  2023.3 

     More details

    Event date: 2023.3

    Language:Japanese  

    Venue:札幌   Country:Japan  

    researchmap

  • システイン化学修飾を利用したタンパク質化学切断法の開発:②Cysホルミル化によるタンパク質配列選択的切断および細胞表層応用

    善明 直輝, 松本 侑也, 安田 斉弘, 内之宮 祥平, 進藤 直哉, 田畑 香織, 王子田 彰夫

    日本薬学会 第143年会(札幌)  2023.3 

     More details

    Event date: 2023.3

    Language:Japanese  

    Venue:札幌   Country:Japan  

    researchmap

  • リジン残基をソルバトクロミック蛍光基へ変換する標的親和性ベンズアルデヒド誘導体の合成と評価

    麻生 真理子, 劉 怡萱, 阿部 由紀子, 田畑 香織

    日本化学会 第103春季年会  2023.3 

     More details

    Event date: 2023.3

    Language:Japanese  

    Country:Japan  

  • リジン残基をソルバトクロミック蛍光基へ変換する標的親和性ベンズアルデヒド誘導体の合成と評価

    麻生 真理子, 劉 怡萱, 阿部 由紀子, 田畑 香織

    日本化学会 第103春季年会  2023.3 

     More details

    Event date: 2023.3

    Language:Japanese  

    Country:Japan  

    researchmap

  • システイン化学修飾によるタンパク質切断法の開発

    松本侑也, 善明直輝, 安田斉弘, 内之宮祥平, 進藤直哉, 田畑香織, 王子田彰夫

    第59回化学関連支部合同九州大会  2022.7 

     More details

    Event date: 2022.7

    Language:Japanese  

    Country:Japan  

  • システイン化学修飾によるタンパク質切断法の開発

    松本侑也, 善明直輝, 安田斉弘, 内之宮祥平, 進藤直哉, 田畑香織, 王子田彰夫

    第59回化学関連支部合同九州大会  2022.7 

     More details

    Event date: 2022.7

    Language:Japanese  

    Country:Japan  

    researchmap

  • 環境応答型solvatochromic 蛍光分子で修飾したDNA 結合性蛋白質の評価

    麻生 真理子・田畑 香織・阿部 由紀子・谷口 陽祐・佐々木 茂貴

    第15回バイオ関連化学シンポジウム  2021.9 

     More details

    Event date: 2021.9

    Language:Japanese  

    Country:Japan  

  • 反応性核酸を用いた環境応答型 solvatochromic 蛍光分子の蛋白質 への導入と修飾蛋白質の評価

    麻生 真理子・金城 綾香・田畑 香織 ・阿部 由紀子 ・谷口 陽祐 ・ 佐々木 茂貴

    第14回バイオ関連化学シンポジウム2020  2020.9 

     More details

    Event date: 2020.9

    Language:Japanese  

    Country:Japan  

  • ハシリドコロ由来新規ポリケタイド合成酵素の構造および機能に関する研究

    田畑香織, 松尾彩加, 田中 宏幸, 森元 聡

    日本薬学会 第136年会  2016.3 

     More details

    Event date: 2016.3

    Language:Japanese  

    Venue:パシフィコ横浜(横浜)   Country:Japan  

  • 活性化に伴いiNOSを発現する細胞をMRIで可視化する方法の開発

    小野健治, 田畑香織, 鈴木弘美, 澤田 誠

    第34回日本神経科学大会  2011.9 

     More details

    Event date: 2011.9

    Language:Others  

    Venue:パシフィコ横浜   Country:Japan  

  • 青色光照射によるChR2発現アストロサイトの活性化制御に関する解析

    小野 健治, 比嘉 円, 田畑 香織, 鈴木 弘美, 澤田 誠

    第33回日本分子生物学会年会、第83回日本生化学会大会 合同大会  2010.12 

     More details

    Event date: 2010.12

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Venue:神戸ポートアイランド   Country:Japan  

  • 青色光照射によるChR2発現アストロサイトの活性化制御に関する検討

    小野 健治, 比嘉 円, 田畑 香織, 鈴木 弘美, 澤田 誠

    第33回日本神経科学大会、第53回日本神経化学大会、第20回日本神経回路学会大会 合同大会  2010.9 

     More details

    Event date: 2010.9

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Venue:神戸コンベンションセンター   Country:Japan  

  • 組換え抗paclitaxel Fabの構築とその機能評価

    田中 宏幸, 田畑 香織, 森元 聡

    日本薬学会第133年会  2013.3 

     More details

    Language:Japanese  

    Country:Japan  

  • 免疫化学的手法によるチャット鑑別法の開発

    Paudel MK, 田中宏幸, 田畑香織, 森元聡, 代田修, 関田節子

    日本生薬学会 第59回年会  2012.9 

     More details

    Language:Japanese  

    Country:Japan  

  • THCA誘導性植物ネクローシスに関する研究

    田中宏幸, 相星彩佳, 田畑香織, 森元聡, 畠中孝彰, 伊東祐二

    日本生薬学会 第59回年会  2012.9 

     More details

    Language:Japanese  

    Country:Japan  

  • Preparation of a recombinant Fab against the anti-malarial drugs, artemisinin and artesunate and their application International conference

    Tanaka H, Paudel MK, Takei A, Sakoda J, Juengwatanatrakul T, Sasaki-Tabata K, Putalun W, Shoyama Y, Morimoto S

    2012 International Congress on Natural Products Research  2012.7 

     More details

    Language:English  

    Country:Japan  

  • Molecular cloning and expression of O-methyltransferases from opium poppy

    Pongkitwitoon B, Sakamoto S, Sasaki K, Tanaka H, Morimoto S

    The XVI International Congress "PHYTOPHARM 2012  2012.7 

     More details

    Language:English  

    Country:Russian Federation  

  • ケシ由来O-Methyltransferase の遺伝子クローニングと発現

    Pongkitwitoon B, 坂元 政一, 佐々木香織, 田中宏幸, 森元聡

    日本薬学会第132年会  2012.3 

     More details

    Language:Japanese  

    Country:Japan  

  • コガネバナβ-glucuronidaseの反応メカニズムに関する研究

    今村聡, 今村麻美, 坂元政一, 田畑香織, 田中宏幸, 森元聡

    日本薬学会第132年会  2012.3 

     More details

    Language:Japanese  

    Country:Japan  

  • カンナビノイドの生育阻害の機能解明

    峰真也, 田畑香織, 田中宏幸, 森元聡

    日本薬学会第132年会  2012.3 

     More details

    Language:Japanese  

    Country:Japan  

  • 植物ネクローシスにおけるcyclophilinDの機能解析

    加藤梨那, 中村俊介, 相星彩佳, 田畑香織, 田中宏幸, 森元聡

    日本生薬学会 第60回年会  2013.9 

     More details

    Language:Japanese  

    Country:Japan  

  • ケシにおけるモルヒネ代謝酵素に関する研究

    戸切祥恵, 山下未知, 清水 瑠美, 安達基泰, 黒木良太, 田畑香織, 田中宏幸, 森元聡

    日本生薬学会第60回年会  2013.9 

     More details

    Language:Japanese  

    Country:Japan  

  • 植物ネクローシスにおける cyclophilin D の機能解析

    加藤梨那, 中村俊介, 相星彩佳, 坂元政一, 田畑 香織, 田中 宏幸, 森元 聡

    日本薬学会第134年会  2014.3 

     More details

    Language:Japanese  

    Country:Japan  

  • 新規D-アミノ酸分析法開発を目指した抗D-セリンモノクローナル抗体の作製

    常浦祐未, 田畑 香織, 坂元政一, 田中 宏幸, 麻生 真理子, 末宗 洋, 森元 聡

    日本薬学会第134年会  2014.3 

     More details

    Language:Japanese  

    Country:Japan  

  • Preparation of antibodies to paclitaxel International conference

    Hiroyuki Tanaka, Chao Z, Kaori Tabata, satoshi morimoto

    2013 International Congress on Natural Products Research  2013.7 

     More details

    Language:English  

    Country:Japan  

  • Construction of a single-chain variable fragment antibody against daidzin and its potential use in an enzyme-linked immunosorbent assay International conference

    Pongkitwitoon B, Kaori Tabata, Hiroyuki Tanaka, satoshi morimoto

    61st International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research  2013.9 

     More details

    Language:English  

    Country:Japan  

  • 植物ネクローシスにおけるcyclophilin Dの機能解析と抗体作製

    加藤梨那, 中村俊介, 相星彩佳, 坂元政一, 田畑香織, 田中 宏幸, 森元 聡

    日本生薬学会 第61回年会  2014.9 

     More details

    Language:Japanese  

    Venue:福岡大学(福岡)   Country:Japan  

  • Exosomeを介した血液脳関門における薬物トランスポーター発現制御機構の解明

    廣田 豪, 水野 颯人, 田畑 香織, 家入 一郎

    TDM研究  2023.6  (一社)日本TDM学会

     More details

    Language:Japanese  

▼display all

MISC

  • Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution

    Kosugi Y., Plianchaisuk A., Putri O., Uriu K., Kaku Y., Hinay A.A., Chen L., Kuramochi J., Sadamasu K., Yoshimura K., Asakura H., Nagashima M., Ito J., Misawa N., Guo Z., Tolentino J.E.M., Fujita S., Pan L., Suganami M., Chiba M., Yoshimura R., Yasuda K., Iida K., Ohsumi N., Strange A.P., Tanaka S., Fukuhara T., Tamura T., Suzuki R., Suzuki S., Ito H., Matsuno K., Sawa H., Nao N., Tanaka S., Tsuda M., Wang L., Oda Y., Ferdous Z., Shishido K., Nakagawa S., Shirakawa K., Takaori-Kondo A., Nagata K., Nomura R., Horisawa Y., Tashiro Y., Kawai Y., Takayama K., Hashimoto R., Deguchi S., Watanabe Y., Sakamoto A., Yasuhara N., Hashiguchi T., Suzuki T., Kimura K., Sasaki J., Nakajima Y., Yajima H., Irie T., Kawabata R., Tabata K., Ikeda T., Nasser H., Shimizu R., Begum M.M., Jonathan M., Mugita Y., Takahashi O., Ichihara K., Ueno T., Motozono C., Toyoda M., Saito A., Shofa M., Shibatani Y., Nishiuchi T., Sato K.

    The Lancet Microbe   5 ( 4 )   2024.4

     More details

    Publisher:The Lancet Microbe  

    DOI: 10.1016/S2666-5247(23)00373-7

    Scopus

Professional Memberships

  • The Molecular Biology Society of Japan

  • The Japanese Society of Pharmacognosy

  • The Pharmaceutical Society of Japan

  • The Pharmaceutical Society of Japan

      More details

  • The Japanese Society of Pharmacognosy

      More details

  • The Molecular Biology Society of Japan

      More details

▼display all

Committee Memberships

  • 九州大学   廃棄物・劇毒物管理委員会  

    2022.4 - 2024.3   

      More details

    Committee type:Other

    researchmap

  • 九州大学   廃棄物・劇毒物管理委員会  

    2020.4 - 2022.3   

      More details

    Committee type:Other

    researchmap

Academic Activities

  • その他

    日本薬学会 第143年会(札幌)  ( Japan ) 2023.3

     More details

    Type:Competition, symposium, etc. 

  • 日本薬学会 第143年会(札幌)

    ( 札幌 Japan ) 2023.3

     More details

    Type:Competition, symposium, etc. 

    researchmap

  • Other International contribution

    The 6th Japan-Taiwan Joint Symposium for Pharmaceutical Sciences  ( Japan Japan ) 2021.8

     More details

    Type:Competition, symposium, etc. 

Research Projects

  • 腎障害時に起こる脳疾患の新規発症メカニズムの解明に向けて

    Grant number:24K09960  2024 - 2026

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    田畑 香織

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    腎障害患者が脳疾患を発症することが多く見られるが、詳しいメカニズムは不明である。そこで、臓器間相互作用において重要な役割を担っているエクソソームが腎と脳のコミュニケーションにも重要であると考えた。腎障害時に腎細胞から分泌されるエクソソームが血液脳関門での遺伝子やタンパク質の発現に影響を及ぼすと仮説を立て、この仮説を明らかにすることで、脳疾患発症の原因解明へつながることが期待される。

    CiNii Research

  • 潜在反応の細胞内タンパク質有機化学の開拓

    Grant number:22K18339  2022 - 2024

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Challenging Research(Pioneering)

    王子田 彰夫, 田畑 香織

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

    CiNii Research

  • Advanced personalized medicine for therapeutic drug monitoring based on quantification of plasma exosomal miRNAs

    Grant number:21K19339  2021 - 2022

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Challenging Research(Exploratory)

    Ieiri Ichiro

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

    In this study, we demonstrated that serum-derived exosomes regulate the expression of drug transporters that contribute to the distribution of drugs to the blood-brain barrier (BBB), and investigated the expression of miRNAs in exosomes derived from serum and BBB cells. Our results showed that the expression of multidrug resistance protein (MRP), a drug transporter known to be highly expressed in the BBB, was increased by the exposure of serum-derived exosomes. In addition, a miRNA array using exosomes detected miRNAs with more than a two-fold difference in expression between serum and BBB. miRNA binding prediction database (miRWalk, miRDB, TargetScan) analysis predicted that this miRNA bind to MRP mRNA.

    CiNii Research

  • トロパン骨格の生合成に関与する酵素の構造機能研究

    2015

    出産・育児復帰者支援

      More details

    Authorship:Principal investigator  Grant type:On-campus funds, funds, etc.

  • トロパン骨格の生合成に関与する酵素の構造機能研究

    2015

    研究補助者雇用支援(短期)

      More details

    Authorship:Principal investigator  Grant type:On-campus funds, funds, etc.

  • トロパン骨格の生合成に関与する酵素の構造機能研究および非天然型化合物群の創出

    Grant number:26870425  2014 - 2016

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 福岡大学総合科学研究チームⅣ

    2013

      More details

    Grant type:Donation

  • 内藤記念女性研究者研究助成金/大麻成分のがん細胞に対する細胞死誘導活性およびがん転移抑制活性に関する研究

    2012

      More details

    Grant type:Donation

  • 新規抗ガン剤開発に向けたヘパラナーゼの構造基盤の解明

    Grant number:23790048  2011 - 2013

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • プライモソーム複合体による停止したDNA複製を再開するための分子メカニズムの解明

    2008 - 2010

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for JSPS Fellows

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

▼display all

Educational Activities

  • 遺伝子のクローニングや組換えタンパク質の発現系の構築、遺伝子やタンパク質の発現解析等について学部学生、大学院生の指導を行っている。

Class subject

  • 先端研究実験I

    2023.4 - 2024.3   Full year

  • 先端研究実験I

    2022.4 - 2023.3   Full year

  • 基礎化学実験

    2013.4 - 2013.9   First semester

  • 基礎化学実験

    2012.4 - 2012.9   First semester

  • 基礎化学実験

    2011.4 - 2011.9   First semester

FD Participation

  • 2025.1   Role:Participation   Title:第7回創薬産学官連携セミナー

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2024.11   Role:Participation   Title:部局FD講演会

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2024.5   Role:Participation   Title:課題協学科目 FD

  • 2023.11   Role:Participation   Title:第2回薬学部局FD講演会「機関間連携」

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2023.8   Role:Participation   Title:令和5年度馬出地区4部局合同男女共同参画FD「九大男女共同参画のこれまでとこれから」

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.11   Role:Participation   Title:第4回創薬産学官連携セミナー

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.11   Role:Participation   Title:第4回創薬産学官連携セミナー(アカデミア創薬)

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.4   Role:Participation   Title:薬学FD「学生の多様性に対応した教育とは:障害学生への合理的配慮を中心に」

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.4   Role:Participation   Title:学生の多様性に対応した教育とは:障害学生への合理的配慮を中心に

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.3   Role:Participation   Title:第3回創薬産学官連携セミナー(感染症研究拠点WG共催)

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.3   Role:Participation   Title:第3回創薬産学官連携セミナー(感染症研究拠点WG共催)

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2022.2   Role:Participation   Title:令和3年度馬出地区4部局合同男女共同参画FD

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2021.9   Role:Participation   Title:JST 次世代研究者挑戦的研究プログラム 説明会

    Organizer:University-wide

  • 2021.9   Role:Participation   Title:次世代研究者挑戦的研究プログラムに関する説明会

    Organizer:University-wide

  • 2021.5   Role:Participation   Title:第2回創薬産学官連携セミナー

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2021.5   Role:Participation   Title:第2回創薬産学官連携セミナー

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2021.2   Role:Participation   Title:創薬産学官連携セミナー

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2021.2   Role:Participation   Title:創薬産学官連携セミナー

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2020.11   Role:Participation   Title:令和2年度馬出地区4部局合同男女共同参画FD

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2019.10   Role:Speech   Title:馬出地区4部局合同男女共同参画FD

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2016.2   Role:Participation   Title:ダイバーシティ推進のための意識改革FD「大学改革と男女共同参画の推進」

    Organizer:University-wide

  • 2016.2   Role:Participation   Title:「山縣由美子理事のプレゼン応援講座」

    Organizer:University-wide

  • 2016.2   Role:Participation   Title:女性研究者研究力向上セミナー 「基礎から学ぶ英語論文集中講座」

    Organizer:University-wide

  • 2015.6   Role:Participation   Title:FD講演会「製薬業界の環境変化を受けた今後のMR活動とメディカルアフェアーズの確立について」

    Organizer:[Undergraduate school/graduate school/graduate faculty]

  • 2013.6   Role:Participation   Title:女性リーダーのためのアサーティブ・コミュニケーション

    Organizer:University-wide

  • 2012.9   Role:Participation   Title:女性研究者英語能力向上セミナーⅢ

    Organizer:University-wide

  • 2010.9   Role:Participation   Title:スキルアップセミナー「女性教員のためのFD講習会」

    Organizer:University-wide

  • 2010.7   Role:Participation   Title:第33回認定実務実習指導薬剤師養成ワークショップin九州(福岡)

▼display all

Outline of Social Contribution and International Cooperation activities

  • 2022年度より、九州大学のJTWプログラムのホストファミリーとして留学生を受け入れている。

Travel Abroad

  • 2017.4 - 2019.3

    Staying countory name 1:Austria   Staying institution name 1:IST Austria